Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
7 Countries Where You Can Buy a Home for Under $100,000 - 2Passenger Missing After Going Overboard Disney Cruise Ship
- 3Report: Russian military pressuring students to work as drone pilots
- 4The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- 5EU states agree first step for Ukraine reparations fund
- Artemis II astronauts make long-distance call to the space station as they head home from the moon
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- Tourist trade in Greece and Cyprus suffering from Iran war effects
- Pain at the pump for Hampton Roads residents
- What's Your #1 Pizza Beating Mix?
- Step by step instructions to Pick the Right Web-based Degree Program
- Some Americans say they'll go without health insurance as ACA rates spike
- Vote In favor of Your Favored Distributed computing Administration
